How does it work?
PT-141 (bremelanotide) activates melanocortin receptors in the brain rather than acting on blood flow.
What does the research say?
Published studies, strongest evidence first.
- Randomised trial
Two phase 3 trials in 1,267 premenopausal women: desire scores rose slightly more than on placebo; nausea, flushing and headache were more common.
Obstet Gynecol, 2019 · PubMed - Review
An independent re-analysis of the same trials found the benefits modest and dropouts from side effects much higher than on placebo.
J Sex Res, 2021 · PubMed
What should you know?
- There are randomised trials in people, the strongest kind of evidence.
- For research and education, not medical advice. Talk to a health professional before using any peptide.
Frequently asked questions
What is PT-141?
A melanocortin-receptor peptide tested in phase 3 trials for low desire in women; an independent re-analysis found the benefit modest.
How strong is the evidence for PT-141?
There are randomised trials in people, the strongest kind of evidence. This summary covers 2 published studies, each labelled by study type.
Is PT-141 registered with BPOM?
No. PT-141 from Continue is a research-grade compound, not a medicine, and is not registered with BPOM.
Where can I buy PT-141 with a COA in Indonesia?
Continue sells research-grade PT-141 with a COA for every batch, shipped cold across Indonesia.
